Dr. Michael Ahlijanian, Ph.D. is a veteran neuroscience drug developer with over 30 years of R&D experience, including senior leadership roles at Pfizer, and Bristol Myers Squibb and biotech companies such as Forma Therapeutics and Pinteon Therapeutics. He has overseen preclinical and early clinical development programs in Alzheimer’s, Parkinson’s, and ALS.